Guy Oliver

Conduit Pharmaceuticals

Joanne Holland

Conduit Pharmaceuticals has appointed Joanne Holland as chief scientific officer. Holland brings two decades of pharmaceutical experience to her new position. She most recently served as vice president of R&D at Conduit Pharmaceuticals. Earlier in her career, Holland held the position of chief scientific officer at Nuformix.

Domain Therapeutics

Stephan Schann

Domain Therapeutics has appointed Stephan Schann as chief scientific officer. Schann brings over two decades of experience in biomedical research to his new position. He most recently served as vice president of research at the company following on from his position as director of R&D. Prior to Domain, Schann was head of medicinal chemistry at Faust Pharmaceuticals.

Ocugen

Huma Qamar

Ocugen has appointed Huma Qamar as chief medical officer. Qamar brings nearly two decades of experience in multiple therapeutic areas to her new position. She most recently served as chief scientific officer, head of R&D at Medicus Pharma. Earlier in her career Qamar worked in a variety of roles at Fox Chase Cancer Center.

Shattuck Labs

Kate Sasser

Shattuck Labs has appointed Kate Sasser to its board of directors. Sasser brings over two decades of experience in biological sciences to her new position. She currently serves as chief scientific officer at Tempus Labs. Prior to this, Sasser served as senior vice president, head of translational research and precision medicine and R&D operations at Genmab.

Shattuck Labs

Clay Siegall

Shattuck Labs has appointed Clay Siegall to its board of directors. Siegall holds a wealth of experience in drug development and in multiple leadership positions. He currently serves as president, chief executive officer and chairman of the board of Immunome. Prior to this, he held the positions of chief executive officer and president at Seagen.

Asceneuron

Henrik Zetterberg

Asceneuron has appointed Henrik Zetterberg to its scientific advisory board. Zetterberg holds a wealth of experience. He is currently a professor of neurochemistry at the University of Gothenburg and University College London, and serves as a clinical chemist at Sahlgrenska University Hospital. Zetterberg is also a member of the Hong Kong Center for Neurodegenerative Diseases.

Asceneuron

Christopher van Dyck

Asceneuron has appointed Christopher van Dyck to its scientific advisory board. Van Dyck holds a wealth of experience in areas including Alzheimer’s disease. He currently serves as professor of psychiatry, neurology and neuroscience and director of the Alzheimer’s Disease Research Unit and the division of ageing and geriatric psychiatry at Yale School of Medicine.

Asceneuron

Rik Ossenkoppele

Asceneuron has appointed Rik Ossenkoppele to its scientific advisory board. Ossenkoppele brings over a decade of experience in areas of neuroimaging, biomarkers and cognition in Alzheimer’s disease to his new position. He currently serves as an associate professor in translational neuroscience and principal investigator at Amsterdam University Medical Center, as well as Lund University.